Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and Treatment of Latent Tuberculosis Infection

  • Lee, Seung Heon (Division of Pulmonary, Sleep, and Critical Care Medicine, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine)
  • Received : 2015.02.10
  • Accepted : 2015.03.09
  • Published : 2015.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

A small number of viable tuberculosis bacilli can reside in an individual with latent tuberculosis infection (LTBI) without obvious clinical symptoms or abnormal chest radiographs. Diagnosis and treatment for LTBI are important for tuberculosis (TB) control in public and private health, especially in high-risk populations. The updated 2014 Korean guidelines for TB recommend that tuberculin skin tests, interferon-gamma release assays, or a combination of the two can be used for LTBI diagnosis according to age and immune status of the host as well as TB contact history. The regimens for LTBI treatment include isoniazid, rifampicin, or isoniazid/rifampicin. However, results of drug susceptibility test from the index case must be considered in selecting the appropriate drug for recent contacts. Standardized LTBI diagnosis and treatment based on the new 2014 guidelines will contribute to the effective TB control in Korea as well as to the establishment of updated guidelines.

Keywords

References

  1. Sutherland I. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 1976;19:1-63.
  2. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis. Lancet 2003;362:887-99. https://doi.org/10.1016/S0140-6736(03)14333-4
  3. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
  4. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. Seoul: Korean Centers for Disease Control and Prevention; 2011.
  5. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention; 2014.
  6. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998;2:27-36.
  7. Choi CM, Kang CI, Kim DH, Kim CH, Kim HJ, Lee CH, et al. The role of TST in the diagnosis of latent tuberculosis tion among military personnel in South Korea. Int J Tuberc Lung Dis 2006;10:1342-6.
  8. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006;28:24-30. https://doi.org/10.1183/09031936.06.00016906
  9. Lee SW, Oh SY, Lee JB, Choi CM, Kim HJ. Tuberculin skin test distribution following a change in BCG vaccination policy. PLoS One 2014;9:e86419. https://doi.org/10.1371/journal.pone.0086419
  10. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161(4 Pt 2):S221-47. https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  11. Grzybowski S, Fishaut H, Rowe J, Brown A. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis 1971;104:605-8.
  12. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161(4 Pt 1):1376-95. https://doi.org/10.1164/ajrccm.161.4.16141
  13. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the wholeblood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61. https://doi.org/10.1001/jama.293.22.2756
  14. Song S, Jeon D, Kim JW, Kim YD, Kim SP, Cho JS, et al. Performance of confirmatory interferon-gamma release assays in school TB outbreaks. Chest 2012;141:983-8. https://doi.org/10.1378/chest.11-1158
  15. Kim HJ, Lee GH, Ryoo S, Oh SY, Lee JB, Kim JH, et al. Role of confirmatory interferon-gamma release assays in school outbreaks of tuberculosis in South Korea. Int J Tuberc Lung Dis Forthcoming 2015.
  16. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206. https://doi.org/10.1183/09031936.00028510
  17. National Institute for Health and Care Excellence. Clinical guideline 33. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control [Internet]. London: National Institute for Health and Care Excellence; 2011 [cited 2014 Dec 12]. Available from: http://www.nice.org.uk/CG117.
  18. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB gold intube assay in clinical practice. Am J Respir Crit Care Med 2013;187:206-11. https://doi.org/10.1164/rccm.201203-0430OC
  19. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21. https://doi.org/10.1164/ajrccm.159.1.9801120
  20. Kim SY, Park MS, Kim YS, Kim SK, Chang J, Yong D, et al. Tuberculin skin test and boosted reactions among newly employed healthcare workers: an observational study. PLoS One 2013;8:e64563. https://doi.org/10.1371/journal.pone.0064563
  21. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd ed. Geneva: World Health Organization; 2014.
  22. Canadian Thoracic Society, The Pulblic Health Agency of Canada and Licensors. Canadian tuberculosis standards. 7th ed. Ottawa: Pulblic Health Agency of Canada; 2014.
  23. American Academy of Pediatrics. Tuberculosis. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, editors. Red Book: 2012 Report of the Committee on Infectious Disease. Elk Grove Village, IL: American Academy of Pediatrics; 2012. p. 736-59.
  24. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep 2010;59:1-25.
  25. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54:1-47.
  26. Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology 2010;15:603-22. https://doi.org/10.1111/j.1440-1843.2010.01751.x
  27. Lee SH, Yim JJ, Kim HJ, Shim TS, Seo HS, Cho YS, et al. Adverse events and development of tuberculosis after 4 months of rifampicin prophylaxis in a tuberculosis outbreak. Epidemiol Infect 2012;140:1028-35. https://doi.org/10.1017/S0950268811001476
  28. Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007;22:779-83. https://doi.org/10.3346/jkms.2007.22.5.779
  29. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007;45:715-22. https://doi.org/10.1086/520983
  30. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155-66. https://doi.org/10.1056/NEJMoa1104875
  31. Jung YJ, Lee JY, Jo KW, Yoo B, Lee CK, Kim YG, et al. The 'either test positive' strategy for latent tuberculous infection before anti-tumour necrosis factor treatment. Int J Tuberc Lung Dis 2014;18:428-34. https://doi.org/10.5588/ijtld.13.0644
  32. Gomez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61. https://doi.org/10.1002/art.22768
  33. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5. https://doi.org/10.1136/thx.2005.046797
  34. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers. Ann Rheum Dis 2003;62:791. https://doi.org/10.1136/ard.62.8.791
  35. Shim TS. Diagnosis and treatment of latent tuberculosis infection due to initiation of anti-TNF therapy. Tuberc Respir Dis 2014;76:261-8. https://doi.org/10.4046/trd.2014.76.6.261
  36. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011;11:1927-35. https://doi.org/10.1111/j.1600-6143.2011.03625.x
  37. Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, et al. Comparison of the tuberculin skin test and interferon-gamma release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013;41:103-10. https://doi.org/10.1007/s15010-012-0291-0
  38. Kim SH, Lee SO, Park IA, Park SJ, Choi SH, Kim YS, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis 2010;12:113-9. https://doi.org/10.1111/j.1399-3062.2010.00495.x

Cited by

  1. Synthesis andIn VitroEvaluation of New Thiosemicarbazone Derivatives as Potential Antimicrobial Agents vol.2016, pp.None, 2015, https://doi.org/10.1155/2016/1692540
  2. Pulmonary Tuberculosis Diagnosis: Where We Are? vol.79, pp.3, 2016, https://doi.org/10.4046/trd.2016.79.3.134
  3. Tuberculosis Infection and Latent Tuberculosis vol.79, pp.4, 2015, https://doi.org/10.4046/trd.2016.79.4.201
  4. Minimizing Tuberculosis Risk in Patients Receiving Anti-TNF Therapy vol.14, pp.5, 2017, https://doi.org/10.1513/annalsats.201701-055ed
  5. Infecção latente por tuberculose entre pessoas com HIV/AIDS, fatores associados e progressão para doença ativa em município no Sul do Brasil vol.33, pp.8, 2015, https://doi.org/10.1590/0102-311x00050916
  6. Poor predictability of QuantiFERON-TB assay in recipients and donors for tuberculosis development after kidney transplantation in an intermediate-TB-burden country vol.18, pp.1, 2015, https://doi.org/10.1186/s12882-017-0506-9
  7. The Use of TB-Specific Antigen/Phytohemagglutinin Ratio for Diagnosis and Treatment Monitoring of Extrapulmonary Tuberculosis vol.9, pp.None, 2015, https://doi.org/10.3389/fimmu.2018.01047
  8. The Prevalence and Risk Factors of Latent Tuberculosis Infection among Health Care Workers Working in a Tertiary Hospital in South Korea vol.81, pp.4, 2015, https://doi.org/10.4046/trd.2018.0020
  9. Pre-immigration Screening for Tuberculosis in South Korea: A Comparison of Smear- and Culture-Based Protocols vol.82, pp.2, 2019, https://doi.org/10.4046/trd.2018.0009
  10. Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/2034950
  11. Analysis of a mathematical model for tuberculosis with diagnosis vol.59, pp.1, 2019, https://doi.org/10.1007/s12190-018-1172-1
  12. Adverse event and treatment completion rates of a 12-dose weekly isoniazid and rifapentine course for South Korean healthcare workers vol.158, pp.None, 2015, https://doi.org/10.1016/j.rmed.2019.10.005
  13. Prevalence and Risk Factors of Latent Tuberculosis Infection among Healthcare Workers vol.24, pp.2, 2015, https://doi.org/10.14192/kjicp.2019.24.2.52
  14. 잠복결핵감염 양성인 분진작업 근로자에서 활동성 결핵 발병률 vol.30, pp.1, 2020, https://doi.org/10.15269/jksoeh.2020.30.1.67
  15. Disseminated Tuberculosis in a Psoriasis Patient under Adalimumab Treatment despite the Chemoprophylaxis of Latent Tuberculosis: A Case Report vol.33, pp.1, 2015, https://doi.org/10.5021/ad.2021.33.1.77
  16. The burden and predictors of latent tuberculosis infection among immigrants in South Korea: a retrospective cross-sectional study vol.21, pp.1, 2015, https://doi.org/10.1186/s12879-021-06922-x